Update on neurological paraneoplastic syndromes

Current Opinion in Oncology

Volumn 27, Issue 6, 2015, Pages 489-495

  Höftberger, Romana ^a   Rosenfeld, Myrna R ^b   Dalmau, Josep ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Limbic encephalitis; Onconeuronal antibodies; Paraneoplastic cerebellar degeneration; Paraneoplastic neurological syndromes; Sensory neuronopathy

Indexed keywords

ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; CANCER IMMUNOTHERAPY; CELL SURFACE; CEREBELLUM DEGENERATION; COGNITIVE DEFECT; DEPRESSION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IRRITABILITY; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARANEOPLASTIC NEUROPATHY; PARESTHESIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEIZURE; SENSORY DYSFUNCTION; SHORT TERM MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 84944055919     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000222     Document Type: Review

References (49)

1. Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004; 6:55-62.
2. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13:682-690.
3. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257:509-517.
4. Armangue T, Leypoldt F, Malaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014; 75:317-323.
5. Steinman L. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease. Eur J Immunol 2014; 44:3201-3205.
6. Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010; 67:330-335.
7. Monstad SE, Knudsen A, Salvesen HB, et al. Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 2009; 58:1795-1800.
8. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13:167-177.
9. Armangue T, Santamaria J, Dalmau J. When a serum test overrides the clinical assessment. Neurology 2015; 84:1379-1381.
10. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135-1140.
11. Lancaster E, Dalmau J. Neuronal autoantigens: pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8:380-390.
12. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology 2013; 2:e27384.
13. Zhang L, Qian W, Chen Q, et al. Imbalance in circulating T lymphocyte subsets contributes to Hu antibody-associated paraneoplastic neurological syndromes. Cell Immunol 2014; 290:245-250.
14. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276-286.
15. Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015; 138:94-109.
16. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci 2015; 1338:94-114.
17. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42:1931-1937.
18. de Graaff E, Maat P, Hulsenboom E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71:815-824.
19. Greene M, Lai Y, Baella N, et al. Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. J Am Med Assoc Neurol 2014; 71:1003-1008.
20. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59-72.
21. Pittock SJ, Lucchinetti CF, Lennon VA. Antineuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53:580-587.
22. Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59:764-766.
23. Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161-165.
24. Burk K, Wick M, Roth G, et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010; 257:59-62.
25. Sabater L, Hoftberger R, Boronat A, et al. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One 2013; 8:e60438.
26. Bataller L, Sabater L, Saiz A, et al. Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 2004; 56:575-579.
27. Hoftberger R, Sabater L, Velasco F, et al. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. Neuropathol Appl Neurobiol 2014; 40:650-653.
28. Sabater L, Bataller L, Carpentier AF, et al. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and nonsmall-cell lung cancer. J Neurol Neurosurg Psychiatry 2006; 77:1359-1362.
29. Hoftberger R, Kovacs GG, Sabater L, et al. Protein kinase Cgamma antibodies and paraneoplastic cerebellar degeneration. J Neuroimmunol 2013; 256:91-93.
30. Ducray F, Demarquay G, Graus F, et al. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. Eur J Neurol 2014; 21:731-735.
31. Fu JB, Raj VS, Asher A, et al. Inpatient rehabilitation performance of patients with paraneoplastic cerebellar degeneration. Arch Phys Med Rehabil 2014; 95:2496-2499.
32. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings, and tumor association in 50 patients. Brain 2000; 123:1481-1494.
33. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138-1148.
34. Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214-221.
35. Dalmau J, Gultekin SH, Voltz R, et al. Ma1, a novel neuronal and testis specific protein, is recognized by the serum of patients with paraneoplastic neurologic disorders. Brain 1999; 122:27-39.
36. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831-1844.
37. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65:424-434.
38. Graus F, Boronat A, Xifro X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010; 74:857-859.
39. Hoftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015; 84:2403-2412.
40. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9:776-785.
41. Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013; 81:1500-1506.
42. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9:67-76.
43. Lancaster E, Huijbers MG, Bar V, et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69:303-311.
44. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channelcomplex proteins leucine-rich, glioma inactivated 1 protein and contactinassociated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133:2734-2748.
45. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19-23.
46. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091-1098.
47. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12:157-165.
48. Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013; 162:850-856.
49. Schmitt SE, Pargeon K, Frechette ES. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79:1094-1100.